NCT05664828View on ClinicalTrials.gov

Efficacy of SN132D in Patients With Suspected Endometriosis

PHASE2CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

June 20, 2023

Study Completion Date

September 12, 2023

Conditions

Endometriosis

Interventions

DRUG

SN132D

Manganese-based macromolecular MRI contrast agent

Trial Locations (1)

20501

Kvinnokliniken, Skåne University Hospital, Malmo

All Listed Sponsors

lead

Spago Nanomedical AB

INDUSTRY